Use the hyperlinks, where available to access additional clinical trial information.
A multicenter, single arm, study of daratumumab-lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients who fail bortezomib-based induction therapy
Australasian Leukaemia and Lymphoma Group (ALLG)
This study aims to assess the effectiveness of using a combination of targeted (daratumumab), immunomodulating (lenalidomide) and steroid (dexamethasone) therapies and a stem cell transplant to improve the remission and recurrence rates of Multiple Myeloma in patients that have not responded to the standard induction therapy (Bortezomib). Patients eligible to participate in this study will receive four cycles of daratumumab, lenalidomide and dexamethasone, followed by a stem cell transplant of their own non-cancerous cells and a further 12 cycles of daratumumab, lenalidomide and dexamethasone, with an additional 12 cycles of lenalidomide for maintenance.